Ado-trastuzumab emtansine and Insulin aspart, recombinant Subcutaneous
Determining the interaction of Ado-trastuzumab emtansine and Insulin aspart, recombinant Subcutaneous and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: ado-trastuzumab emtansine
Brand name: Kadcyla
Synonyms: Ado-Trastuzumab Emtansine
Generic Name: insulin aspart
Brand name: Fiasp, NovoLog, NovoLog FlexPen, NovoLog PenFill, NovoLOG FlexTouch, Fiasp PenFill, Fiasp FlexTouch
Synonyms: Insulin aspart, Insulin Aspart
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Ado-trastuzumab emtansine-Insulin degludec
- Ado-trastuzumab emtansine-Insulin Degludec (U-100) Prefilled Pens
- Ado-trastuzumab emtansine-Insulin Degludec (U-100) Vials
- Ado-trastuzumab emtansine-Insulin Degludec (U-200) Prefilled Pens
- Ado-trastuzumab emtansine-Insulin degludec and liraglutide
- Ado-trastuzumab emtansine-Insulin degludec and liraglutide Subcutaneous
- Insulin aspart, recombinant Subcutaneous-Ado-trastuzumab emtansine Intravenous
- Insulin aspart, recombinant Subcutaneous-Adox Pak 2/100
- Insulin aspart, recombinant Subcutaneous-Adoxa
- Insulin aspart, recombinant Subcutaneous-Adoxa CK
- Insulin aspart, recombinant Subcutaneous-Adoxa Pak
- Insulin aspart, recombinant Subcutaneous-Adoxa Pak 1/100